CBUS Earnings

CBUS reported its FY2025Q3 earnings on 2025-11-13, showcasing a revenue of 615.00K against an estimate of 1.00M, resulting in a -55.79% surprise. The EPS was -0.44, surpassing the expected -0.41 by -7.32% . The stock experienced a -2.4% price change on the earnings day and a 1.6% change over the next five days, reflecting market reactions to the results.

Following CBUS's FY2025Q3 earnings announcement on 2025-11-13, the stock price moved by -2.40% on the day of the release. Over the subsequent five days, it saw a 1.60% change. Historically, CBUS's stock price tends to shift by an average of +0.09% in the 10 days leading up to earnings and -3.07% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate CBUS’s annual revenue to reach 2.00M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -13.94% and EPS estimates Revise Upward by 5.45% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between CBUS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -13.94%, while EPS estimates moved Revise Upward by 5.45% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CBUS's stock price typically moves by +0.09% in the 10 days before its earnings and -3.07% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 2.00M.

The earnings call summary indicates a positive outlook with significant cost reductions, improved net loss, and strategic focus on future revenue streams, particularly from rice herbicide traits and biofragrance programs. The Q&A reveals optimism about R&D collaborations, regulatory progress, and market potential, despite some uncertainties in financing specifics. The strong potential for royalty revenue and commercial expansion, coupled with reduced expenses, suggests a positive stock movement over the next two weeks.